Biology of brain metastases and novel targeted therapies: Time to translate the research

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1835, Issue 1, 2013, Pages 61-75

  Fokas, Emmanouil ^a   Steinbach, Joachim P ^a   Rödel, Claus ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Angiogenesis; Blood brain barrier; Brain metastases; Radiotherapy; Targeted therapies

Indexed keywords

BEVACIZUMAB; BROXURIDINE; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CRIZOTINIB; DABRAFENIB; EFAPROXIRAL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; IPILIMUMAB; LAPATINIB; LONIDAMINE; METALLOPROTEINASE; NEUROTRANSMITTER; NEUROTROPHIN; NITROSOUREA; PROTEOHEPARAN SULFATE; SAGOPILONE; SORAFENIB; SUNITINIB; TEGAFUR; TEMOZOLOMIDE; TRANSFERASE INHIBITOR; TRASTUZUMAB; UNINDEXED DRUG; VEMURAFENIB; VORINOSTAT;

ANGIOGENESIS; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BRAIN PARENCHYMA; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CANCER RADIOTHERAPY; CELLULAR DISTRIBUTION; DRUG MECHANISM; DRUG PENETRATION; EXTRACELLULAR MATRIX; EXTRAVASATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NONHUMAN; PARENCHYMA; PATHOGENESIS; PRIORITY JOURNAL; RADIOSENSITIZATION; REVIEW; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84869870044     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.10.005     Document Type: Review

References (253)

1. Walker A.E., Robins M., Weinfeld F.D. Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 1985, 35:219-226.
2. Gavrilovic I.T., Posner J.B. Brain metastases: epidemiology and pathophysiology. J. Neurooncol. 2005, 75:5-14.
3. Gaspar L.E., Mehta M.P., Patchell R.A., Burri S.H., Robinson P.D., Morris R.E., Ammirati M., Andrews D.W., Asher A.L., Cobbs C.S., Kondziolka D., Linskey M.E., Loeffler J.S., McDermott M., Mikkelsen T., Olson J.J., Paleologos N.A., Ryken T.C., Kalkanis S.N. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J. Neurooncol. 2010, 96:17-32.
4. Soffietti R., Ruda R., Trevisan E. Brain metastases: current management and new developments. Curr. Opin. Oncol. 2008, 20:676-684.
5. Barnholtz-Sloan J.S., Sloan A.E., Davis F.G., Vigneau F.D., Lai P., Sawaya R.E. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J. Clin. Oncol. 2004, 22:2865-2872.
6. Melisko M.E., Glantz M., Rugo H.S. New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat. Clin. Pract. Oncol. 2009, 6:25-33.
7. Delattre J.Y., Krol G., Thaler H.T., Posner J.B. Distribution of brain metastases. Arch. Neurol. 1988, 45:741-744.
8. Steeg P.S., Camphausen K.A., Smith Q.R. Brain metastases as preventive and therapeutic targets. Nat. Rev. Cancer 2011, 11:352-363.
9. Langer C.J., Mehta M.P. Current management of brain metastases, with a focus on systemic options. J. Clin. Oncol. 2005, 23:6207-6219.
10. Gaspar L., Scott C., Rotman M., Asbell S., Phillips T., Wasserman T., McKenna W.G., Byhardt R. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 1997, 37:745-751.
11. Sul J., Posner J.B. Brain metastases: epidemiology and pathophysiology. Cancer Treat. Res. 2007, 136:1-21.
12. Patchell R.A., Tibbs P.A., Walsh J.W., Dempsey R.J., Maruyama Y., Kryscio R.J., Markesbery W.R., Macdonald J.S., Young B. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 1990, 322:494-500.
13. Andrews D.W., Scott C.B., Sperduto P.W., Flanders A.E., Gaspar L.E., Schell M.C., Werner-Wasik M., Demas W., Ryu J., Bahary J.P., Souhami L., Rotman M., Mehta M.P., Curran W.J. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363:1665-1672.
14. Aoyama H., Shirato H., Tago M., Nakagawa K., Toyoda T., Hatano K., Kenjyo M., Oya N., Hirota S., Shioura H., Kunieda E., Inomata T., Hayakawa K., Katoh N., Kobashi G. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006, 295:2483-2491.
15. Kocher M., Soffietti R., Abacioglu U., Villa S., Fauchon F., Baumert B.G., Fariselli L., Tzuk-Shina T., Kortmann R.D., Carrie C., Ben Hassel M., Kouri M., Valeinis E., van den Berge D., Collette S., Collette L., Mueller R.P. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J. Clin. Oncol. 2011, 29:134-141.
16. Vecht C.J., Haaxma-Reiche H., Noordijk E.M., Padberg G.W., Voormolen J.H., Hoekstra F.H., Tans J.T., Lambooij N., Metsaars J.A., Wattendorff A.R., et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann. Neurol. 1993, 33:583-590.
17. Fokas E., Henzel M., Surber G., Kleinert G., Hamm K., Engenhart-Cabillic R. Stereotactic radiosurgery and fractionated stereotactic radiotherapy: comparison of efficacy and toxicity in 260 patients with brain metastases. J. Neurooncol. 2012, 109:91-98.
18. Soffietti R., Trevisan E., Ruda R. Targeted therapy in brain metastasis. Curr. Opin. Oncol. 2012, 24:679-686.
19. Fidler I.J. The role of the organ microenvironment in brain metastasis. Semin. Cancer Biol. 2011, 21:107-112.
20. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
21. Nicolson G.L. Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev. 1988, 7:143-188.
22. Talmadge J.E., Fidler I.J. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010, 70:5649-5669.
23. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2:563-572.
24. Chiang A.C., Massague J. Molecular basis of metastasis. N. Engl. J. Med. 2008, 359:2814-2823.
25. Kienast Y., von Baumgarten L., Fuhrmann M., Klinkert W.E., Goldbrunner R., Herms J., Winkler F. Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. 2010, 16:116-122.
26. Leenders W.P., Kusters B., Verrijp K., Maass C., Wesseling P., Heerschap A., Ruiter D., Ryan A., de Waal R. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin. Cancer Res. 2004, 10:6222-6230.
27. Fidler I.J., Yano S., Zhang R.D., Fujimaki T., Bucana C.D. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 2002, 3:53-57.
28. Essig M., Anzalone N., Combs S.E., Dorfler A., Lee S.K., Picozzi P., Rovira A., Weller M., Law M. MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice. AJNR Am. J. Neuroradiol. 2012, 33:803-817.
29. Neves S., Mazal P.R., Wanschitz J., Rudnay A.C., Drlicek M., Czech T., Wustinger C., Budka H. Pseudogliomatous growth pattern of anaplastic small cell carcinomas metastatic to the brain. Clin. Neuropathol. 2001, 20:38-42.
30. J.N.D.A.T.o.T.W.B.S.C. Ewing, Philadelphia and London, 1928.
31. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989, 8:98-101.
32. Fidler I.J., Gruys E., Cifone M.A., Barnes Z., Bucana C. Demonstration of multiple phenotypic diversity in a murine melanoma of recent origin. J. Natl. Cancer Inst. 1981, 67:947-956.
33. Fidler I.J. Selection of successive tumour lines for metastasis. Nat. New Biol. 1973, 242:148-149.
34. Nicolson G.L., Brunson K.W., Fidler I.J. Specificity of arrest, survival, and growth of selected metastatic variant cell lines. Cancer Res. 1978, 38:4105-4111.
35. Duda D.G., Duyverman A.M., Kohno M., Snuderl M., Steller E.J., Fukumura D., Jain R.K. Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21677-21682.
36. Izraely S., Sagi-Assif O., Klein A., Meshel T., Tsarfaty G., Pasmanik-Chor M., Nahmias C., Couraud P.O., Ateh E., Bryant J.L., Hoon D.S., Witz I.P. The metastatic microenvironment: brain-residing melanoma metastasis and dormant micrometastasis. Int. J. Cancer 2012, 131:1071-1082.
37. Lorger M., Felding-Habermann B. Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am. J. Pathol. 2010, 176:2958-2971.
38. Klos K.J., O'Neill B.P. Brain metastases. Neurologist 2004, 10:31-46.
39. Bender E.T., Tome W.A. Distribution of brain metastases: implications for non-uniform dose prescriptions. Br. J. Radiol. 2011, 84:649-658.
40. Weller R.O., Djuanda E., Yow H.Y., Carare R.O. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol. 2009, 117:1-14.
41. Deeken J.F., Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res. 2007, 13:1663-1674.
42. Abbott N.J., Ronnback L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006, 7:41-53.
43. Risau W., Wolburg H. Development of the blood-brain barrier. Trends Neurosci. 1990, 13:174-178.
44. Engelhardt B., Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin. Immunopathol. 2009, 31:497-511.
45. Pardridge W.M. Molecular biology of the blood-brain barrier. Mol. Biotechnol. 2005, 30:57-70.
46. Hawkins B.T., Davis T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 2005, 57:173-185.
47. Weiss N., Miller F., Cazaubon S., Couraud P.O. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim. Biophys. Acta 2009, 1788:842-857.
48. Wolburg H., Noell S., Mack A., Wolburg-Buchholz K., Fallier-Becker P. Brain endothelial cells and the glio-vascular complex. Cell Tissue Res. 2009, 335:75-96.
49. Caswell P.T., Vadrevu S., Norman J.C. Integrins: masters and slaves of endocytic transport. Nat. Rev. Mol. Cell Biol. 2009, 10:843-853.
50. Rathinam R., Alahari S.K. Important role of integrins in the cancer biology. Cancer Metastasis Rev. 2010, 29:223-237.
51. Yoshimasu T., Sakurai T., Oura S., Hirai I., Tanino H., Kokawa Y., Naito Y., Okamura Y., Ota I., Tani N., Matsuura N. Increased expression of integrin alpha3beta1 in highly brain metastatic subclone of a human non-small cell lung cancer cell line. Cancer Sci. 2004, 95:142-148.
52. Lorger M., Krueger J.S., O'Neal M., Staflin K., Felding-Habermann B. Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:10666-10671.
53. Kusters B., Westphal J.R., Smits D., Ruiter D.J., Wesseling P., Keilholz U., de Waal R.M. The pattern of metastasis of human melanoma to the central nervous system is not influenced by integrin alpha(v)beta(3) expression. Int. J. Cancer 2001, 92:176-180.
54. Wu Y.J., Muldoon L.L., Gahramanov S., Kraemer D.F., Marshall D.J., Neuwelt E.A. Targeting alpha(V)-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model. J. Neurooncol. 2012, 110:27-36.
55. Witz I.P. The selectin-selectin ligand axis in tumor progression. Cancer Metastasis Rev. 2008, 27:19-30.
56. Laubli H., Borsig L. Selectins promote tumor metastasis. Semin. Cancer Biol. 2010, 20:169-177.
57. Liu Z.J., Tian R., Li Y., An W., Zhuge Y., Livingstone A.S., Velazquez O.C. Inhibition of tumor angiogenesis and melanoma growth by targeting vascular E-selectin. Ann. Surg. 2011, 254:450-456. (discussion 456-457).
58. Keeley E.C., Mehrad B., Strieter R.M. CXC chemokines in cancer angiogenesis and metastases. Adv. Cancer Res. 2010, 106:91-111.
59. Lee B.C., Lee T.H., Avraham S., Avraham H.K. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells. Mol. Cancer Res. 2004, 2:327-338.
60. Hinton C.V., Avraham S., Avraham H.K. Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin. Exp. Metastasis 2010, 27:97-105.
61. Hartmann T.N., Burger J.A., Glodek A., Fujii N., Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 2005, 24:4462-4471.
62. Salmaggi A., Maderna E., Calatozzolo C., Gaviani P., Canazza A., Milanesi I., Silvani A., DiMeco F., Carbone A., Pollo B. CXCL12, CXCR4 and CXCR7 expression in brain metastases. Cancer Biol. Ther. 2009, 8:1608-1614.
63. Carbonell W.S., Ansorge O., Sibson N., Muschel R. The vascular basement membrane as "soil" in brain metastasis. PLoS One 2009, 4:e5857.
64. Bos P.D., Zhang X.H., Nadal C., Shu W., Gomis R.R., Nguyen D.X., Minn A.J., van de Vijver M.J., Gerald W.L., Foekens J.A., Massague J. Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459:1005-1009.
65. Drinnan N.B., Halliday J., Ramsdale T. Inhibitors of sialyltransferases: potential roles in tumor growth and metastasis. Mini Rev. Med. Chem. 2003, 3:501-517.
66. Rolland Y., Demeule M., Fenart L., Beliveau R. Inhibition of melanoma brain metastasis by targeting melanotransferrin at the cell surface. Pigment Cell Melanoma Res. 2009, 22:86-98.
67. Li B., Zhao W.D., Tan Z.M., Fang W.G., Zhu L., Chen Y.H. Involvement of Rho/ROCK signalling in small cell lung cancer migration through human brain microvascular endothelial cells. FEBS Lett. 2006, 580:4252-4260.
68. Mehrotra J., Vali M., McVeigh M., Kominsky S.L., Fackler M.J., Lahti-Domenici J., Polyak K., Sacchi N., Garrett-Mayer E., Argani P., Sukumar S. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin. Cancer Res. 2004, 10:3104-3109.
69. Ding L., Ellis M.J., Li S., Larson D.E., Chen K., Wallis J.W., Harris C.C., McLellan M.D., Fulton R.S., Fulton L.L., Abbott R.M., Hoog J., Dooling D.J., Koboldt D.C., Schmidt H., Kalicki J., Zhang Q., Chen L., Lin L., Wendl M.C., McMichael J.F., Magrini V.J., Cook L., McGrath S.D., Vickery T.L., Appelbaum E., Deschryver K., Davies S., Guintoli T., Crowder R., Tao Y., Snider J.E., Smith S.M., Dukes A.F., Sanderson G.E., Pohl C.S., Delehaunty K.D., Fronick C.C., Pape K.A., Reed J.S., Robinson J.S., Hodges J.S., Schierding W., Dees N.D., Shen D., Locke D.P., Wiechert M.E., Eldred J.M., Peck J.B., Oberkfell B.J., Lolofie J.T., Du F., Hawkins A.E., O'Laughlin M.D., Bernard K.E., Cunningham M., Elliott G., Mason M.D., Thompson D.M., Ivanovich J.L., Goodfellow P.J., Perou C.M., Weinstock G.M., Aft R., Watson M., Ley T.J., Wilson R.K., Mardis E.R. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464:999-1005.
70. Steeg P.S. Metastasis suppressors alter the signal transduction of cancer cells. Nat. Rev. Cancer 2003, 3:55-63.
71. Steeg P.S. Perspectives on classic article: metastasis suppressor genes. J Natl. Cancer Inst. 2004, 96:E4.
72. Stark A.M., Tongers K., Maass N., Mehdorn H.M., Held-Feindt J. Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases. J. Cancer Res. Clin. Oncol. 2005, 131:191-198.
73. Lee J.H., Miele M.E., Hicks D.J., Phillips K.K., Trent J.M., Weissman B.E., Welch D.R. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J. Natl. Cancer Inst. 1996, 88:1731-1737.
74. Sarris M., Scolyer R.A., Konopka M., Thompson J.F., Harper C.G., Lee C.S. Cytoplasmic expression of nm23 predicts the potential for cerebral metastasis in patients with primary cutaneous melanoma. Melanoma Res. 2004, 14:23-27.
75. Stark A.M., Pfannenschmidt S., Tscheslog H., Maass N., Rosel F., Mehdorn H.M., Held-Feindt J. Reduced mRNA and protein expression of BCL-2 versus decreased mRNA and increased protein expression of BAX in breast cancer brain metastases: a real-time PCR and immunohistochemical evaluation. Neurol. Res. 2006, 28:787-793.
76. Navab R., Liu J., Seiden-Long I., Shih W., Li M., Bandarchi B., Chen Y., Lau D., Zu Y.F., Cescon D., Zhu C.Q., Organ S., Ibrahimov E., Ohanessian D., Tsao M.S. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia 2009, 11:1292-1300.
77. Friedl P., Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011, 147:992-1009.
78. Bonneh-Barkay D., Wiley C.A. Brain extracellular matrix in neurodegeneration. Brain Pathol. 2009, 19:573-585.
79. Frischknecht R., Gundelfinger E.D. The brain's extracellular matrix and its role in synaptic plasticity. Adv. Exp. Med. Biol. 2012, 970:153-171.
80. Friedl P., Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat. Rev. Mol. Cell Biol. 2009, 10:445-457.
81. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
82. Lee K.Y., Kim Y.J., Yoo H., Lee S.H., Park J.B., Kim H.J. Human brain endothelial cell-derived COX-2 facilitates extravasation of breast cancer cells across the blood-brain barrier. Anticancer. Res. 2011, 31:4307-4313.
83. Xie T.X., Huang F.J., Aldape K.D., Kang S.H., Liu M., Gershenwald J.E., Xie K., Sawaya R., Huang S. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 2006, 66:3188-3196.
84. Arnold S.M., Young A.B., Munn R.K., Patchell R.A., Nanayakkara N., Markesbery W.R. Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 in paired primary tumors and brain metastasis. Clin. Cancer Res. 1999, 5:4028-4033.
85. Mendes O., Kim H.T., Lungu G., Stoica G. MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2. Clin. Exp. Metastasis 2007, 24:341-351.
86. Stark A.M., Anuszkiewicz B., Mentlein R., Yoneda T., Mehdorn H.M., Held-Feindt J. Differential expression of matrix metalloproteinases in brain- and bone-seeking clones of metastatic MDA-MB-231 breast cancer cells. J. Neurooncol. 2007, 81:39-48.
87. Tester A.M., Waltham M., Oh S.J., Bae S.N., Bills M.M., Walker E.C., Kern F.G., Stetler-Stevenson W.G., Lippman M.E., Thompson E.W. Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice. Cancer Res. 2004, 64:652-658.
88. Arvatz G., Shafat I., Levy-Adam F., Ilan N., Vlodavsky I. The heparanase system and tumor metastasis: is heparanase the seed and soil?. Cancer Metastasis Rev. 2011, 30:253-268.
89. Ridgway L.D., Wetzel M.D., Marchetti D. Modulation of GEF-H1 induced signaling by heparanase in brain metastatic melanoma cells. J. Cell. Biochem. 2010, 111:1299-1309.
90. Zhang L., Sullivan P., Suyama J., Marchetti D. Epidermal growth factor-induced heparanase nucleolar localization augments DNA topoisomerase I activity in brain metastatic breast cancer. Mol. Cancer Res. 2010, 8:278-290.
91. Marchetti D., Reiland J., Erwin B., Roy M. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues. Int. J. Cancer 2003, 104:167-174.
92. Zhang L., Sullivan P.S., Goodman J.C., Gunaratne P.H., Marchetti D. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res. 2011, 71:645-654.
93. Drell T.L.t., Joseph J., Lang K., Niggemann B., Zaenker K.S., Entschladen F. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res. Treat. 2003, 80:63-70.
94. Denkins Y., Reiland J., Roy M., Sinnappah-Kang N.D., Galjour J., Murry B.P., Blust J., Aucoin R., Marchetti D. Brain metastases in melanoma: roles of neurotrophins. Neuro Oncol. 2004, 6:154-165.
95. Marchetti D., Nicolson G.L. Neurotrophin stimulation of human melanoma cell invasion: selected enhancement of heparanase activity and heparanase degradation of specific heparan sulfate subpopulations. Adv. Enzyme Regul. 1997, 37:111-134.
96. Kerbel R.S. Tumor angiogenesis. N. Engl. J. Med. 2008, 358:2039-2049.
97. Goel S., Duda D.G., Xu L., Munn L.L., Boucher Y., Fukumura D., Jain R.K. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 2011, 91:1071-1121.
98. Potente M., Gerhardt H., Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146:873-887.
99. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
100. Fokas E., McKenna W.G., Muschel R.J. The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies. Cancer Metastasis Rev. 2012, 31:823-842.
101. Salgado K.B., Toscani N.V., Silva L.L., Hilbig A., Barbosa-Coutinho L.M. Immunoexpression of endoglin in brain metastasis secondary to malignant melanoma: evaluation of angiogenesis and comparison with brain metastasis secondary to breast and lung carcinomas. Clin. Exp. Metastasis 2007, 24:403-410.
102. Jubb A.M., Cesario A., Ferguson M., Congedo M.T., Gatter K.C., Lococo F., Mule A., Pezzella F. Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. Br. J. Cancer 2011, 104:1877-1881.
103. Monsky W.L., Mouta Carreira C., Tsuzuki Y., Gohongi T., Fukumura D., Jain R.K. Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin. Cancer Res. 2002, 8:1008-1013.
104. McCurley C.R., Shivers R.R., Del Maestro R.F. Quantitative comparison of the morphology of the microvasculature of primary lung lesions and metastatic brain tumours. J. Submicrosc. Cytol. Pathol. 1998, 30:257-269.
105. Liu Y., Carson-Walter E.B., Cooper A., Winans B.N., Johnson M.D., Walter K.A. Vascular gene expression patterns are conserved in primary and metastatic brain tumors. J. Neurooncol. 2010, 99:13-24.
106. Zhang M., Olsson Y. Reactions of astrocytes and microglial cells around hematogenous metastases of the human brain. Expression of endothelin-like immunoreactivity in reactive astrocytes and activation of microglial cells. J. Neurol. Sci. 1995, 134:26-32.
107. Seike T., Fujita K., Yamakawa Y., Kido M.A., Takiguchi S., Teramoto N., Iguchi H., Noda M. Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis. Clin. Exp. Metastasis 2011, 28:13-25.
108. Cruz-Munoz W., Jaramillo M.L., Man S., Xu P., Banville M., Collins C., Nantel A., Francia G., Morgan S.S., Cranmer L.D., O'Connor-McCourt M., Kerbel R.S. Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma. Cancer Res. 2012, 72:4909-4919.
109. Schackert G., Simmons R.D., Buzbee T.M., Hume D.A., Fidler I.J. Macrophage infiltration into experimental brain metastases: occurrence through an intact blood-brain barrier. J. Natl. Cancer Inst. 1988, 80:1027-1034.
110. Brantley E.C., Guo L., Zhang C., Lin Q., Yokoi K., Langley R.R., Kruzel E., Maya M., Kim S.W., Kim S.J., Fan D., Fidler I.J. Nitric oxide-mediated tumoricidal activity of murine microglial cells. Transl. Oncol. 2010, 3:380-388.
111. Murata J., Corradin S.B., Janzer R.C., Juillerat-Jeanneret L. Tumor cells suppress cytokine-induced nitric-oxide (NO) production in cerebral endothelial cells. Int. J. Cancer 1994, 59:699-705.
112. Pukrop T., Dehghani F., Chuang H.N., Lohaus R., Bayanga K., Heermann S., Regen T., Van Rossum D., Klemm F., Schulz M., Siam L., Hoffmann A., Trumper L., Stadelmann C., Bechmann I., Hanisch U.K., Binder C. Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way. Glia 2010, 58:1477-1489.
113. Fitzgerald D.P., Palmieri D., Hua E., Hargrave E., Herring J.M., Qian Y., Vega-Valle E., Weil R.J., Stark A.M., Vortmeyer A.O., Steeg P.S. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin. Exp. Metastasis 2008, 25:799-810.
114. Berghoff A.S., Lassmann H., Preusser M., Hoftberger R. Characterization of the inflammatory response to solid cancer metastases in the human brain. Clin. Exp. Metastasis 2012, (Epub ahead of print).
115. Lin Q., Balasubramanian K., Fan D., Kim S.J., Guo L., Wang H., Bar-Eli M., Aldape K.D., Fidler I.J. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia 2010, 12:748-754.
116. Kim S.J., Kim J.S., Park E.S., Lee J.S., Lin Q., Langley R.R., Maya M., He J., Kim S.W., Weihua Z., Balasubramanian K., Fan D., Mills G.B., Hung M.C., Fidler I.J. Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia 2011, 13:286-298.
117. Francia G., Cruz-Munoz W., Man S., Xu P., Kerbel R.S. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat. Rev. Cancer 2011, 11:135-141.
118. Cruz-Munoz W., Man S., Xu P., Kerbel R.S. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res. 2008, 68:4500-4505.
119. Cruz-Munoz W., Man S., Kerbel R.S. Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens. Clin. Cancer Res. 2009, 15:4867-4874.
120. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J. Clin. Oncol. 2009, 27:5278-5286.
121. Cheng X., Hung M.C. Breast cancer brain metastases. Cancer Metastasis Rev. 2007, 26:635-643.
122. Melisko M.E., Moore D.H., Sneed P.K., De Franco J., Rugo H.S. Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J. Neurooncol. 2008, 88:359-365.
123. Dawood S., Lei X., Litton J.K., Buchholz T.A., Hortobagyi G.N., Gonzalez-Angulo A.M. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer 2012, 118:4652-4659.
124. Dawood S., Ueno N.T., Valero V., Andreopoulou E., Hsu L., Lara J., Woodward W., Buchholz T.A., Hortobagyi G.N., Cristofanilli M. Incidence of and survival following brain metastases among women with inflammatory breast cancer. Ann. Oncol. 2010, 21:2348-2355.
125. Tomasello G., Bedard P.L., de Azambuja E., Lossignol D., Devriendt D., Piccart-Gebhart M.J. Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib. Crit. Rev. Oncol. Hematol. 2010, 75:110-121.
126. Dawood S., Gonzalez-Angulo A.M., Albarracin C., Yu T.K., Hortobagyi G.N., Buchholz T.A., Woodward W.A. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer 2010, 116:3084-3092.
127. Eichler A.F., Kuter I., Ryan P., Schapira L., Younger J., Henson J.W. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 2008, 112:2359-2367.
128. Palmieri D., Bronder J.L., Herring J.M., Yoneda T., Weil R.J., Stark A.M., Kurek R., Vega-Valle E., Feigenbaum L., Halverson D., Vortmeyer A.O., Steinberg S.M., Aldape K., Steeg P.S. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res. 2007, 67:4190-4198.
129. Kennecke H., Yerushalmi R., Woods R., Cheang M.C., Voduc D., Speers C.H., Nielsen T.O., Gelmon K. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 2010, 28:3271-3277.
130. Yap Y.S., Cornelio G.H., Devi B.C., Khorprasert C., Kim S.B., Kim T.Y., Lee S.C., Park Y.H., Sohn J.H., Sutandyo N., Wong D.W., Kobayashi M., Landis S.H., Yeoh E.M., Moon H., Ro J. Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br. J. Cancer 2012, 107:1075-1082.
131. Tarhan M.O., Demir L., Somali I., Yigit S., Erten C., Alacacioglu A., Ellidokuz H., Seseogullari O., Kucukzeybek Y., Can A., Dirican A., Bayoglu V., Akyol M. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival. Clin. Exp. Metastasis 2012, 100:1092-1103.
132. Gril B., Palmieri D., Bronder J.L., Herring J.M., Vega-Valle E., Feigenbaum L., Liewehr D.J., Steinberg S.M., Merino M.J., Rubin S.D., Steeg P.S. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl. Cancer Inst. 2008, 100:1092-1103.
133. Taskar K.S., Rudraraju V., Mittapalli R.K., Samala R., Thorsheim H.R., Lockman J., Gril B., Hua E., Palmieri D., Polli J.W., Castellino S., Rubin S.D., Lockman P.R., Steeg P.S., Smith Q.R. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm. Res. 2012, 29:770-781.
134. Cameron D., Casey M., Press M., Lindquist D., Pienkowski T., Romieu C.G., Chan S., Jagiello-Gruszfeld A., Kaufman B., Crown J., Chan A., Campone M., Viens P., Davidson N., Gorbounova V., Raats J.I., Skarlos D., Newstat B., Roychowdhury D., Paoletti P., Oliva C., Rubin S., Stein S., Geyer C.E. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 2008, 112:533-543.
135. Lin N.U., Carey L.A., Liu M.C., Younger J., Come S.E., Ewend M., Harris G.J., Bullitt E., Van den Abbeele A.D., Henson J.W., Li X., Gelman R., Burstein H.J., Kasparian E., Kirsch D.G., Crawford A., Hochberg F., Winer E.P. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 2008, 26:1993-1999.
136. Crivellari D., Spazzapan S., Lombardi D., Militello L., Torrisi E., Russo A.E., Sorio R., Talamini R., Miolo G., Carli P., Veronesi A. Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience. Tumori 2012, 98:33-38.
137. Bachelot G.R.T.D., Campone M., Dieras V., Cropet C., Roche H.H., Jimenez M., Le Rhun E., Pierga J., Gonçalves A., Leheurteur M., Domont J., Gutierrez M., Cure H., Ferrero J., Labbe C. LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR). J. Clin. Oncol. 2011, 29. (Suppl.; abstr 509).
138. Metzger-Filho O., Tutt A., de Azambuja E., Saini K.S., Viale G., Loi S., Bradbury I., Bliss J.M., Azim H.A., Ellis P., Di Leo A., Baselga J., Sotiriou C., Piccart-Gebhart M. Dissecting the heterogeneity of triple-negative breast cancer. J. Clin. Oncol. 2012, 30:1879-1887.
139. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol. Oncol. 2011, 5:387-393.
140. Chalmers A.J., Lakshman M., Chan N., Bristow R.G. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin. Radiat. Oncol. 2010, 20:274-281.
141. Shaheen M., Allen C., Nickoloff J.A., Hromas R. Synthetic lethality: exploiting the addiction of cancer to DNA repair. Blood 2011, 117:6074-6082.
142. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27:5459-5468.
143. Palmieri D., Lockman P.R., Thomas F.C., Hua E., Herring J., Hargrave E., Johnson M., Flores N., Qian Y., Vega-Valle E., Taskar K.S., Rudraraju V., Mittapalli R.K., Gaasch J.A., Bohn K.A., Thorsheim H.R., Liewehr D.J., Davis S., Reilly J.F., Walker R., Bronder J.L., Feigenbaum L., Steinberg S.M., Camphausen K., Meltzer P.S., Richon V.M., Smith Q.R., Steeg P.S. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin. Cancer Res. 2009, 15:6148-6157.
144. Qian Y., Hua E., Bisht K., Woditschka S., Skordos K.W., Liewehr D.J., Steinberg S.M., Brogi E., Akram M.M., Killian J.K., Edelman D.C., Pineda M., Scurci S., Degenhardt Y.Y., Laquerre S., Lampkin T.A., Meltzer P.S., Camphausen K., Steeg P.S., Palmieri D. Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain. Clin. Exp. Metastasis 2011, 28:899-908.
145. Freedman R.A., Bullitt E., Sun L., Gelman R., Harris G., Ligibel J.A., Krop I.E., Partridge A.H., Eisenberg E., Winer E.P., Lin N.U. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin. Breast Cancer 2011, 11:376-383.
146. Ricciardi S., de Marinis F. Multimodality management of non-small cell lung cancer patients with brain metastases. Curr. Opin. Oncol. 2010, 22:86-93.
147. Louie A.V., Rodrigues G., Yaremko B., Yu E., Dar A.R., Dingle B., Vincent M., Sanatani M., Younus J., Malthaner R., Inculet R. Management and prognosis in synchronous solitary resected brain metastasis from non-small-cell lung cancer. Clin. Lung Cancer 2009, 10:174-179.
148. Mamon H.J., Yeap B.Y., Janne P.A., Reblando J., Shrager S., Jaklitsch M.T., Mentzer S., Lukanich J.M., Sugarbaker D.J., Baldini E.H., Berman S., Skarin A., Bueno R. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J. Clin. Oncol. 2005, 23:1530-1537.
149. Kawabe T., Phi J.H., Yamamoto M., Kim D.G., Barfod B.E., Urakawa Y. Treatment of brain metastasis from lung cancer. Prog. Neurol. Surg. 2012, 25:148-155.
150. Paumier A., Cuenca X., Le Pechoux C. Prophylactic cranial irradiation in lung cancer. Cancer Treat. Rev. 2011, 37:261-265.
151. Ceresoli G.L., Cappuzzo F., Gregorc V., Bartolini S., Crino L., Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann. Oncol. 2004, 15:1042-1047.
152. Wu C., Li Y.L., Wang Z.M., Li Z., Zhang T.X., Wei Z. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 2007, 57:359-364.
153. Grommes C., Oxnard G.R., Kris M.G., Miller V.A., Pao W., Holodny A.I., Clarke J.L., Lassman A.B. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011, 13:1364-1369.
154. Jamal-Hanjani M., Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin. Cancer Res. 2012, 18:938-944.
155. Lai C.S., Boshoff C., Falzon M., Lee S.M. Complete response to erlotinib treatment in brain metastases from recurrent NSCLC. Thorax 2006, 61:91.
156. Fekrazad M.H., Ravindranathan M., Jones D.V. Response of intracranial metastases to erlotinib therapy. J. Clin. Oncol. 2007, 25:5024-5026.
157. Eichler A.F., Kahle K.T., Wang D.L., Joshi V.A., Willers H., Engelman J.A., Lynch T.J., Sequist L.V. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 2010, 12:1193-1199.
158. Kim J.E., Lee D.H., Choi Y., Yoon D.H., Kim S.W., Suh C., Lee J.S. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 2009, 65:351-354.
159. Masuda T., Hattori N., Hamada A., Iwamoto H., Ohshimo S., Kanehara M., Ishikawa N., Fujitaka K., Haruta Y., Murai H., Kohno N. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother. Pharmacol. 2011, 67:1465-1469.
160. Clarke J.L., Pao W., Wu N., Miller V.A., Lassman A.B. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J. Neurooncol. 2010, 99:283-286.
161. Heon S., Yeap B.Y., Britt G.J., Costa D.B., Rabin M.S., Jackman D.M., Johnson B.E. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 2010, 16:5873-5882.
162. Heon S., Yeap B.Y., Lindeman N.I., Joshi V.A., Butaney M., Britt G.J., Costa D.B., Rabin M.S., Jackman D.M., Johnson B.E. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin. Cancer Res. 2012, 18:4406-4414.
163. Yap T.A., Vidal L., Adam J., Stephens P., Spicer J., Shaw H., Ang J., Temple G., Bell S., Shahidi M., Uttenreuther-Fischer M., Stopfer P., Futreal A., Calvert H., de Bono J.S., Plummer R. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J. Clin. Oncol. 2010, 28:3965-3972.
164. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., Ou S.H., Dezube B.J., Janne P.A., Costa D.B., Varella-Garcia M., Kim W.H., Lynch T.J., Fidias P., Stubbs H., Engelman J.A., Sequist L.V., Tan W., Gandhi L., Mino-Kenudson M., Wei G.C., Shreeve S.M., Ratain M.J., Settleman J., Christensen J.G., Haber D.A., Wilner K., Salgia R., Shapiro G.I., Clark J.W., Iafrate A.J. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010, 363:1693-1703.
165. Gandhi L., Janne P.A. Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin. Cancer Res. 2012, 18:3737-3742.
166. Costa D.B., Kobayashi S., Pandya S.S., Yeo W.L., Shen Z., Tan W., Wilner K.D. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J. Clin. Oncol. 2011, 29:e443-e445.
167. Falk A.T., Poudenx M., Otto J., Ghalloussi H., Barriere J. Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report. Lung Cancer 2012, 78:282-284.
168. de la Monte S.M., Moore G.W., Hutchins G.M. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 1983, 43:3427-3433.
169. Eggermont A.M., Robert C. Melanoma in 2011: a new paradigm tumor for drug development. Nat. Rev. Clin. Oncol. 2012, 9:74-76.
170. Alexandru D., Bota D.A., Linskey M.E. Epidemiology of central nervous system metastases. Prog. Neurol. Surg. 2012, 25:13-29.
171. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010, 363:809-819.
172. Long G.V., Menzies A.M., Nagrial A.M., Haydu L.E., Hamilton A.L., Mann G.J., Hughes T.M., Thompson J.F., Scolyer R.A., Kefford R.F. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 2011, 29:1239-1246.
173. Capper D., Berghoff A.S., Magerle M., Ilhan A., Wohrer A., Hackl M., Pichler J., Pusch S., Meyer J., Habel A., Petzelbauer P., Birner P., von Deimling A., Preusser M. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012, 123:223-233.
174. Rochet N.M., Kottschade L.A., Markovic S.N. Vemurafenib for melanoma metastases to the brain. N. Engl. J. Med. 2011, 365:2439-2441.
175. Long G.V., Kefford R.F., Carr P., et al. Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (MUT) BRAF kinase; evidence of activity in melanoma brain metastases (METS) 2010.
176. Falchook G.S., Long G.V., Kurzrock R., Kim K.B., Arkenau T.H., Brown M.P., Hamid O., Infante J.R., Millward M., Pavlick A.C., O'Day S.J., Blackman S.C., Curtis C.M., Lebowitz P., Ma B., Ouellet D., Kefford R.F. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901.
177. Su F., Bradley W.D., Wang Q., Yang H., Xu L., Higgins B., Kolinsky K., Packman K., Kim M.J., Trunzer K., Lee R.J., Schostack K., Carter J., Albert T., Germer S., Rosinski J., Martin M., Simcox M.E., Lestini B., Heimbrook D., Bollag G. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res. 2012, 72:969-978.
178. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., Chen Z., Lee M.K., Attar N., Sazegar H., Chodon T., Nelson S.F., McArthur G., Sosman J.A., Ribas A., Lo R.S. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
179. Johannessen C.M., Boehm J.S., Kim S.Y., Thomas S.R., Wardwell L., Johnson L.A., Emery C.M., Stransky N., Cogdill A.P., Barretina J., Caponigro G., Hieronymus H., Murray R.R., Salehi-Ashtiani K., Hill D.E., Vidal M., Zhao J.J., Yang X., Alkan O., Kim S., Harris J.L., Wilson C.J., Myer V.E., Finan P.M., Root D.E., Roberts T.M., Golub T., Flaherty K.T., Dummer R., Weber B.L., Sellers W.R., Schlegel R., Wargo J.A., Hahn W.C., Garraway L.A. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-972.
180. Flaherty K.T., Robert C., Hersey P., Nathan P., Garbe C., Milhem M., Demidov L.V., Hassel J.C., Rutkowski P., Mohr P., Dummer R., Trefzer U., Larkin J.M., Utikal J., Dreno B., Nyakas M., Middleton M.R., Becker J.C., Casey M., Sherman L.J., Wu F.S., Ouellet D., Martin A.M., Patel K., Schadendorf D. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 2012, 367:107-114.
181. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
182. Tremante E., Ginebri A., Lo Monaco E., Frascione P., Di Filippo F., Terrenato I., Benevolo M., Mottolese M., Pescarmona E., Visca P., Natali P.G., Giacomini P. Melanoma molecular classes and prognosis in the postgenomic era. Lancet Oncol. 2012, 13:e205-e211.
183. Abastado J.P. The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor. Cancer Res. 2012, 72:2159-2161.
184. Jacobs J.F., Nierkens S., Figdor C.G., de Vries I.J., Adema G.J. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. Lancet Oncol. 2012, 13:e32-e42.
185. Fong L., Small E.J. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J. Clin. Oncol. 2008, 26:5275-5283.
186. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbe C., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., Urba W.J. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
187. Robert C., Thomas L., Bondarenko I., O'Day S., Garbe D.J.M.C., Lebbe C., Baurain J.F., Testori A., Grob J.J., Davidson N., Richards J., Maio M., Hauschild A., Miller W.H., Gascon P., Lotem M., Harmankaya K., Ibrahim R., Francis S., Chen T.T., Humphrey R., Hoos A., Wolchok J.D. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364:2517-2526.
188. Lipson E.J., Drake C.G. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin. Cancer Res. 2011, 17:6958-6962.
189. Lebbe M.D., Robert C., Lorigan P., Ottensmeier C.H., Wolchok J.D. Ipilimumab improves survival in previously treated, advanced melanoma patients with poor prognostic factors: subgroup analysis from a phase III trial. Ann. Oncol. 2010, 21. (Suppl.).
190. Di Giacomo A.M., Ascierto P.A., Pilla L., Santinami M., Ferrucci P.F., Giannarelli D., Marasco A., Rivoltini L., Simeone E., Nicoletti S.V., Fonsatti E., Annesi D., Queirolo P., Testori A., Ridolfi R., Parmiani G., Maio M. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 2012, 13:879-886.
191. Margolin K., Ernstoff M.S., Hamid O., Lawrence D., McDermott D., Puzanov I., Wolchok J.D., Clark J.I., Sznol M., Logan T.F., Richards J., Michener T., Balogh A., Heller K.N., Hodi F.S. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012, 13:459-465.
192. Sharma P., Wagner K., Wolchok J.D., Allison J.P. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer 2011, 11:805-812.
193. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
194. Cook K.M., Figg W.D. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J. Clin. 2010, 60:222-243.
195. Ferrara N., Mass R.D., Campa C., Kim R. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu. Rev. Med. 2007, 58:491-504.
196. Kowanetz M., Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res. 2006, 12:5018-5022.
197. Kim L.S., Huang S., Lu W., Lev D.C., Price J.E. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin. Exp. Metastasis 2004, 21:107-118.
198. Yano S., Shinohara H., Herbst R.S., Kuniyasu H., Bucana C.D., Ellis L.M., Davis D.W., McConkey D.J., Fidler I.J. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res. 2000, 60:4959-4967.
199. JuanYin J., Tracy K., Zhang L., Munasinghe J., Shapiro E., Koretsky A., Kelly K. Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clin. Exp. Metastasis 2009, 26:403-414.
200. Carden C.P., Larkin J.M., Rosenthal M.A. What is the risk of intracranial bleeding during anti-VEGF therapy?. Neuro Oncol. 2008, 10:624-630.
201. Besse B., Lasserre S.F., Compton P., Huang J., Augustus S., Rohr U.P. Bevacizumab safety in patients with central nervous system metastases. Clin. Cancer Res. 2010, 16:269-278.
202. De Braganca K.C., Janjigian Y.Y., Azzoli C.G., Kris M.G., Pietanza M.C., Nolan C.P., Omuro A.M., Holodny A.I., Lassman A.B. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J. Neurooncol. 2010, 100:443-447.
203. Gore M.E., Hariharan S., Porta C., Bracarda S., Hawkins R., Bjarnason G.A., Oudard S., Lee S.H., Carteni G., Nieto A., Yuan J., Szczylik C. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011, 117:501-509.
204. Lim Z.D., Mahajan A., Weinberg J., Tannir N.M. Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy. Am. J. Clin. Oncol. 2012, (Epub ahead of print).
205. Stadler W.M., Figlin R.A., McDermott D.F., Dutcher J.P., Knox J.J., Miller W.H., Hainsworth J.D., Henderson C.A., George J.R., Hajdenberg J., Kindwall-Keller T.L., Ernstoff M.S., Drabkin H.A., Curti B.D., Chu L., Ryan C.W., Hotte S.J., Xia C., Cupit L., Bukowski R.M. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010, 116:1272-1280.
206. Knisely J.P., Berkey B., Chakravarti A., Yung A.W., Curran W.J., Robins H.I., Movsas B., Brachman D.G., Henderson R.H., Mehta M.P. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int. J. Radiat. Oncol. Biol. Phys. 2008, 71:79-86.
207. Jain R.K., di Tomaso E., Duda D.G., Loeffler J.S., Sorensen A.G., Batchelor T.T. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 2007, 8:610-622.
208. Carmeliet P., Jain R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 2011, 10:417-427.
209. Quant E.C., Wen P.Y. Response assessment in neuro-oncology. Curr. Oncol. Rep. 2011, 13:50-56.
210. Aoyama H., Shirato H., Onimaru R., Kagei K., Ikeda J., Ishii N., Sawamura Y., Miyasaka K. Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull. Int. J. Radiat. Oncol. Biol. Phys. 2003, 56:793-800.
211. Linskey M.E., Andrews D.W., Asher A.L., Burri S.H., Kondziolka D., Robinson P.D., Ammirati M., Cobbs C.S., Gaspar L.E., Loeffler J.S., McDermott M., Mehta M.P., Mikkelsen T., Olson J.J., Paleologos N.A., Patchell R.A., Ryken T.C., Kalkanis S.N. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J. Neurooncol. 2010, 96:45-68.
212. Kalkanis S.N., Kondziolka D., Gaspar L.E., Burri S.H., Asher A.L., Cobbs C.S., Ammirati M., Robinson P.D., Andrews D.W., Loeffler J.S., McDermott M., Mehta M.P., Mikkelsen T., Olson J.J., Paleologos N.A., Patchell R.A., Ryken T.C., Linskey M.E. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J. Neurooncol. 2010, 96:33-43.
213. Fokas E., Henzel M., Surber G., Kleinert G., Hamm K., Engenhart-Cabillic R. Stereotactic radiosurgery and fractionated stereotactic radiotherapy: comparison of efficacy and toxicity in 260 patients with brain metastases. J. Neurooncol. 2012, 109:91-98.
214. Bhangoo S.S., Linskey M.E., Kalkanis S.N. Evidence-based guidelines for the management of brain metastases. Neurosurg. Clin. N. Am. 2011, 22:97-104. (viii).
215. Evens A.M. Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer. Curr. Opin. Oncol. 2004, 16:576-580.
216. Magda D., Miller R.A. Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin. Cancer Biol. 2006, 16:466-476.
217. Mehta M.P., Rodrigus P., Terhaard C.H., Rao A., Suh J., Roa W., Souhami L., Bezjak A., Leibenhaut M., Komaki R., Schultz C., Timmerman R., Curran W., Smith J., Phan S.C., Miller R.A., Renschler M.F. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J. Clin. Oncol. 2003, 21:2529-2536.
218. Mehta M.P., Shapiro W.R., Phan S.C., Gervais R., Carrie C., Chabot P., Patchell R.A., Glantz M.J., Recht L., Langer C., Sur R.K., Roa W.H., Mahe M.A., Fortin A., Nieder C., Meyers C.A., Smith J.A., Miller R.A., Renschler M.F. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int. J. Radiat. Oncol. Biol. Phys. 2009, 73:1069-1076.
219. Bernhard E.J., Mitchell J.B., Deen D., Cardell M., Rosenthal D.I., Brown J.M. Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent. Cancer Res. 2000, 60:86-91.
220. Hou H., Khan N., O'Hara J.A., Grinberg O.Y., Dunn J.F., Abajian M.A., Wilmot C.M., Demidenko E., Lu S., Steffen R.P., Swartz H.M. Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int. J. Radiat. Oncol. Biol. Phys. 2005, 61:1503-1509.
221. Rosenberg A., Knox S. Radiation sensitization with redox modulators: a promising approach. Int. J. Radiat. Oncol. Biol. Phys. 2006, 64:343-354.
222. Shaw E., Scott C., Suh J., Kadish S., Stea B., Hackman J., Pearlman A., Murray K., Gaspar L., Mehta M., Curran W., Gerber M. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J. Clin. Oncol. 2003, 21:2364-2371.
223. Suh J.H., Stea B., Nabid A., Kresl J.J., Fortin A., Mercier J.P., Senzer N., Chang E.L., Boyd A.P., Cagnoni P.J., Shaw E. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J. Clin. Oncol. 2006, 24:106-114.
224. Scott C., Suh J., Stea B., Nabid A., Hackman J. Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases. Am. J. Clin. Oncol. 2007, 30:580-587.
225. DeAngelis L.M., Currie V.E., Kim J.H., Krol G., O'Hehir M.A., Farag F.M., Young C.W., Posner J.B. The combined use of radiation therapy and lonidamine in the treatment of brain metastases. J. Neurooncol. 1989, 7:241-247.
226. Mansi J.L., de Graeff A., Newell D.R., Glaholm J., Button D., Leach M.O., Payne G., Smith I.E. A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer. Br. J. Cancer 1991, 64:593-597.
227. Eyre H.J., Ohlsen J.D., Frank J., LoBuglio A.F., McCracken J.D., Weatherall T.J., Mansfield C.M. Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain. A Southwest Oncology Group study. J. Neurooncol. 1984, 2:325-330.
228. Komarnicky L.T., Phillips T.L., Martz K., Asbell S., Isaacson S., Urtasun R. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int. J. Radiat. Oncol. Biol. Phys. 1991, 20:53-58.
229. Phillips T.L., Scott C.B., Leibel S.A., Rotman M., Weigensberg I.J. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. Int. J. Radiat. Oncol. Biol. Phys. 1995, 33:339-348.
230. Olson J.J., Paleologos N.A., Gaspar L.E., Robinson P.D., Morris R.E., Ammirati M., Andrews D.W., Asher A.L., Burri S.H., Cobbs C.S., Kondziolka D., Linskey M.E., Loeffler J.S., McDermott M., Mehta M.P., Mikkelsen T., Patchell R.A., Ryken T.C., Kalkanis S.N. The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J. Neurooncol. 2010, 96:115-142.
231. Baschnagel A., Russo A., Burgan W.E., Carter D., Beam K., Palmieri D., Steeg P.S., Tofilon P., Camphausen K. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol. Cancer Ther. 2009, 8:1589-1595.
232. Neuwelt E.A. Mechanisms of disease: the blood-brain barrier. Neurosurgery 2004, 54:131-140. (discussion 141-132).
233. Muldoon L.L., Soussain C., Jahnke K., Johanson C., Siegal T., Smith Q.R., Hall W.A., Hynynen K., Senter P.D., Peereboom D.M., Neuwelt E.A. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J. Clin. Oncol. 2007, 25:2295-2305.
234. Blakeley J. Drug delivery to brain tumors. Curr. Neurol. Neurosci. Rep. 2008, 8:235-241.
235. Fortin D. The blood-brain barrier: its influence in the treatment of brain tumors metastases. Curr. Cancer Drug Targets 2012, 12:247-259.
236. Gerstner E.R., Fine R.L. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J. Clin. Oncol. 2007, 25:2306-2312.
237. Agarwal S., Sane R., Gallardo J.L., Ohlfest J.R., Elmquist W.F. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J. Pharmacol. Exp. Ther. 2010, 334:147-155.
238. Lagas J.S., van Waterschoot R.A., Sparidans R.W., Wagenaar E., Beijnen J.H., Schinkel A.H. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol. Cancer Ther. 2010, 9:319-326.
239. Minocha M., Khurana V., Qin B., Pal D., Mitra A.K. Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib. Int. J. Pharm. 2012, 436:127-134.
240. Zhang R.D., Price J.E., Fujimaki T., Bucana C.D., Fidler I.J. Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am. J. Pathol. 1992, 141:1115-1124.
241. Serres S., Soto M.S., Hamilton A., McAteer M.A., Carbonell W.S., Robson M.D., Ansorge O., Khrapitchev A., Bristow C., Balathasan L., Weissensteiner T., Anthony D.C., Choudhury R.P., Muschel R.J., Sibson N.R. Molecular MRI enables early and sensitive detection of brain metastases. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:6674-6679.
242. Serres S., Soto M.S., Hamilton A., McAteer M.A., Carbonell W.S., Robson M.D., Ansorge O., Khrapitchev A., Bristow C., Balathasan L., Weissensteiner T., Anthony D.C., Choudhury R.P., Muschel R.J., Sibson N.R. Molecular MRI enables early and sensitive detection of brain metastases. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:6674-6679.
243. Bertrand Y., Currie J.C., Poirier J., Demeule M., Abulrob A., Fatehi D., Stanimirovic D., Sartelet H., Castaigne J.P., Beliveau R. Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1. Br. J. Cancer 2011, 105:1697-1707.
244. Thomas F.C., Taskar K., Rudraraju V., Goda S., Thorsheim H.R., Gaasch J.A., Mittapalli R.K., Palmieri D., Steeg P.S., Lockman P.R., Smith Q.R. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm. Res. 2009, 26:2486-2494.
245. Kurzrock R., Gabrail N., Chandhasin C., Moulder S., Smith C., Brenner A., Sankhala K., Mita A., Elian K., Bouchard D., Sarantopoulos J. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol. Cancer Ther. 2012, 11:308-316.
246. Hu J., Ljubimova J.Y., Inoue S., Konda B., Patil R., Ding H., Espinoza A., Wawrowsky K.A., Patil C., Ljubimov A.V., Black K.L. Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models. PLoS One 2010, 5:e10108.
247. Black K.L., Yin D., Ong J.M., Hu J., Konda B.M., Wang X., Ko M.K., Bayan J.A., Sacapano M.R., Espinoza A., Irvin D.K., Shu Y. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res. 2008, 1230:290-302.
248. McDannold N., Arvanitis C.D., Vykhodtseva N., Livingstone M.S. Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res. 2012, 72:3652-3663.
249. Schackert G., Fidler I.J. Site-specific metastasis of mouse melanomas and a fibrosarcoma in the brain or meninges of syngeneic animals. Cancer Res. 1988, 48:3478-3484.
250. Kawaguchi T., Kawaguchi M., Lembo T.M., Nicolson G.L. Differential tumor growth of blood-borne B16 melanoma variants in cerebral dura mater is related to tumor-host cell reactions. Clin. Exp. Metastasis 1989, 7:1-14.
251. Siegal T., Sandbank U., Gabizon A., Mizrachi R., Ben-David E., Catane R. Alteration of blood-brain-CSF barrier in experimental meningeal carcinomatosis. A morphologic and adriamycin-penetration study. J. Neurooncol. 1987, 4:233-242.
252. Schabet M., Herrlinger U. Animal models of leptomeningeal metastasis. J. Neurooncol. 1998, 38:199-205.
253. Schackert G., Price J.E., Bucana C.D., Fidler I.J. Unique patterns of brain metastasis produced by different human carcinomas in athymic nude mice. Int. J. Cancer 1989, 44:892-897.